Oncology Drugs - Burundi

Burundi

The projected revenue in the Oncology Drugs market in Burundi is expected to reach US$3.22m in 2024.
With an annual growth rate (CAGR 2024-2029) of 7.90%, the market volume is estimated to reach US$4.71m by 2029.
In global comparison, United States is expected to generate the highest revenue of US$103,900.00m in 2024.
Despite limited access to advanced oncology drugs, Burundi is witnessing an increasing demand for affordable and locally available treatment options.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Oncology Drugs in Burundi has been increasing steadily over the past few years.

Customer preferences: Cancer is a growing concern in Burundi, and the demand for Oncology Drugs has been increasing as a result. Customers in Burundi are becoming more aware of cancer and the need for early detection and treatment. As a result, they are increasingly seeking out Oncology Drugs to treat the disease.

Trends in the market: The Oncology Drugs market in Burundi has been growing steadily over the past few years. This growth can be attributed to several factors, including an increase in cancer cases, a growing awareness of cancer, and an increase in the availability of Oncology Drugs. As a result of these factors, the market for Oncology Drugs in Burundi is expected to continue to grow in the coming years.

Local special circumstances: Burundi is a low-income country with a high burden of disease. The country has a limited healthcare infrastructure, and many people do not have access to basic healthcare services. This has led to a high mortality rate from cancer, as many people are not diagnosed until the disease is in its advanced stages. However, the government of Burundi is working to improve the healthcare infrastructure and increase access to healthcare services, which is expected to drive demand for Oncology Drugs in the coming years.

Underlying macroeconomic factors: Burundi is a small, landlocked country in East Africa. The country has a low GDP per capita and is heavily dependent on agriculture. However, the government of Burundi is working to diversify the economy and attract foreign investment. This is expected to drive economic growth and increase demand for Oncology Drugs in the coming years. Additionally, the government is working to improve the business environment and reduce barriers to entry, which is expected to increase competition in the Oncology Drugs market and drive down prices.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.